A Detailed Analysis of the Hypercalcemia Treatment Market Based on the Rising Hyperparathyroidism Incidences, Advancements in Therapeutic Interventions, and Regulation of Drugs for Hypercalcemia Treatment
Industry: Healthcare
Published Date: February-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 223
Report ID: PMRREP34006
The global hypercalcemia treatment market is forecast to expand at a CAGR of 11.8% and thereby increase from a value of US$18.3 Mn in 2023, to US$40 Mn by the end of 2030.
|
Attributes |
Key Insights |
|
Hypercalcemia Treatment Market Size (2023E) |
US$18.3 Mn |
|
Projected Market Value (2030F) |
US$40.0 Mn |
|
Global Market Growth Rate (CAGR 2023 to 2030) |
11.8% |
|
Historical Market Growth Rate (CAGR 2018 to 2022) |
10.8% |
The global growth of the hypercalcemia treatment market is being propelled by the increasing elderly population. Hypercalcemia, characterized by elevated serum calcium levels exceeding 2.6 mmol/L, poses various health issues such as weakened bones and kidney stones. Treatment modalities encompass pharmaceutical interventions and surgical removal of overactive glands, with blood tests employed for calcium level assessment.
Furthermore, the surge in the global cancer patient population emerges as a significant driver for the hypercalcemia treatment market. The escalating incidences of hypercalcemia and advancements in treatment technologies contribute to the overall market expansion. The market is driven by the increasing prevalence of hypercalcemia, coupled with ongoing developments in treatment methodologies, particularly in response to the growing number of cancer cases worldwide.
Increasing Prevalence of Chronic Diseases, and Rising Geriatric Population
The anticipated rise in the prevalence of chronic diseases, notably cancer, is projected to elevate the incidence of hypercalcemia, consequently fostering growth in the global hypercalcemia treatment market during the forecast period. The increasing prevalence of hypercalcemia, often associated with cancer and other medical conditions, is expected to be a key driver for market expansion.
For example, data from the Centers for Disease Control and Prevention (CDC) in 2018 reported 1,708,921 new cancer cases and 599,265 cancer-related deaths in the US, highlighting the significant impact on hypercalcemia prevalence. The global rise in the aging population has heightened vulnerability to conditions like hypercalcemia. According to the World Health Organization's 2022 data, by 2050, 80% of the elderly population will reside in low- and middle-income countries, indicating a significant demographic shift.
The accelerated pace of population aging, evident in the fact that those aged 60 years and older surpassed the population of children under five years in 2020, is a noteworthy trend. Projections suggest that from 2015 to 2050, the proportion of the global population over 60 years will almost double, rising from 12% to 22%. This demographic shift underscores a potential surge in demand for hypercalcemia treatment as the elderly population expands.
Adverse Medication Effects, Shortage of Healthcare Professionals, and High Therapy Costs
The anticipated revenue growth in the hypercalcemia market may face obstacles attributable to the adverse effects associated with medications employed for its treatment. For instance, Cinacalcet, a medication classified as calcimimetics, is frequently linked to myalgia, stomach upset, and abdominal pain. Moreover, challenges such as a shortage of qualified healthcare professionals, elevated therapy costs, and a heightened risk of misdiagnosis for hypercalcemia are additional factors projected to constrain revenue growth within the market.
Rapidly Expanding Patient Base of Cancers, and Hyperparathyroidism Prevalence to Propose Great Promise
A substantial patient base for hypercalcemia, combined with a high prevalence of cancer and hyperparathyroidism, creates conducive circumstances for market expansion. According to the American Cancer Society, As of January 1, 2022, over 18 million Americans with a history of invasive cancer were alive. The anticipated number of cancer-related deaths in the US for 2023 is approximately 609,820, translating to about 1,670 deaths per day.
Cancer stands as the second most prevalent cause of death in the US, surpassed only by heart disease. Projections for 2023 estimate that 9,910 children (ages 0 to 14 years) and 5,280 adolescents (ages 15 to 19 years) will receive cancer diagnoses, with 1,040 children and 550 adolescents expected to succumb to the disease. Increased research and development endeavors, particularly directed toward innovative therapies addressing notable clinical gaps, are poised to propel market growth.
Furthermore, favorable conditions for market expansion are anticipated with heightened government support, private and public initiatives aimed at increasing awareness regarding routine medical examinations, improved healthcare infrastructure, and an upswing in healthcare spending. These factors collectively present a spectrum of opportunities within the market.
High Prices, Limited Demand, And Varying Distribution Channels Across Countries
In recent times, manufacturers of hypercalcemia drugs have made substantial investments in research to develop alternative pharmacological treatments for surgical interventions. However, upon the development of a hypercalcemia drug, market players encounter a formidable challenge in the prolonged process of customer adoption.
Efficient distribution of hypercalcemia medicines also presents logistical challenges, particularly in terms of manufacturers identifying suitable channels. Independent pharmacies and drug stores tend to refrain from stocking such drugs due to their high prices and limited demand in local markets. Furthermore, logistical arrangements vary across countries, restricting cost recovery from smaller patient pools in specific regions.
Enhancing product portfolios to improve patient compliance and treatment simplicity has opened up new prospects for market participants in recent years. Additionally, the adoption of innovative marketing strategies has facilitated firms in expanding their regional presence and diversifying their product offerings, paving the way for a promising market outlook in the future. Furthermore, the expansion of distribution networks in a less competitive environment is providing advantageous opportunities for drug manufacturers to establish a robust brand presence.
Key players driving product portfolio diversification and consistent product launches have catalyzed the emergence of regional market players in recent times. Moreover, favorable government policies supporting start-up companies and government funding have further fortified the market position of new entrants.
Supply-side Dynamics
Several factors, including the increasing prevalence of hypercalcemia, and the rising geriatric population, all contribute to the dynamic and rapid expansion of the global Hypercalcemia Treatment market. Amgen Inc., Pfizer Inc., Mylan N. V., Sunovion, and Procter and Gamble are market leaders in the manufacturing sector. The countries like the US, Canada, Germany, Japan, China, and France, are significant producers of drugs.
Increasing demand for research and development endeavors focused on pharmaceuticals for hypercalcemia therapy is observed in the US. The presence of major industry players and advanced healthcare infrastructure are additional factors likely to contribute positively to the growth of this regional market. The robust foundation of medical tourism in the UK is anticipated to significantly propel the adoption of healthcare services at an accelerated pace.
Market vendors are intensifying competition by emphasizing factors like competitive pricing and exploring new indications. To expand their presence in the hyperparathyroidism market, numerous vendors are prioritizing extensive research and development efforts and seeking regulatory approvals. Additionally, a significant portion of market players is actively engaged in the development of efficacious treatments for spasticity, addressing substantial unmet medical needs.
Which is the Top Product Type Segment?
Bisphosphonates Continue to be at the Forefront as Combination Therapy Firms up, Especially Across Developed Markets
Bisphosphonates, employed to mitigate bone density loss, are anticipated to maintain their dominant position in the market throughout the forecast period, driven by widespread preference for this treatment. Additionally, the rising adoption of combination therapy for hypercalcemia treatment, involving the concurrent use of two or more drugs, contributes to the growth of the bisphosphonates market. This is particularly pronounced in developed countries where the strong preference for combination therapy further propels the demand for bisphosphonates, given their prevalent use in conjunction with other drugs and therapeutic approaches.
Which is the Leading Distribution Channel?
Hospitals Bring in the Maximum Revenue Owing to Rising Government Expenditure on Hospital Facilities
The increasing prevalence of hospital direct distribution channels, coupled with the ready accessibility of hypercalcemia treatment drugs and government expenditures on hospital facilities, is likely influenced by the rising demand for cancer treatment within hospital settings. This, in turn, is anticipated to drive the demand for hypercalcemia treatment throughout the forecast period.
Robust Healthcare Infrastructure, and Massive Market of Branded Medications Keep North America at the Top
North America is poised to lead the market during the forecast period, driven by a surge in the prevalence of hyperthyroidism, affecting 21.6 individuals per 100,000 annually according to a J Clin Endocrinol Metab report. The market's revenue growth is expected to be fueled by several factors, including the development of branded medications by prominent regional players, robust healthcare infrastructure, a robust product pipeline from key industry participants, increased prescription rates for novel drugs, improved regional reimbursement policies, escalating R&D initiatives for more effective treatment alternatives, and the presence of significant pharmaceutical entities in the region. This growth is further supported by the guidance of major pharmaceutical companies and increased financial backing from government sources.
Asia Pacific Emerges Highly Lucrative on Account of a Growing Number of Players Offering Targeted Drugs
The market in the Asia Pacific region is anticipated to experience revenue growth driven by the expansion of healthcare infrastructure, increased government initiatives, rising healthcare spending, disposable income, and a growing number of players offering targeted and highly effective drugs. In 2022, health expenditure in China reached approximately 7.05% of the GDP, up from 6.7% the previous year.
India is poised to closely follow China in the sales of hypercalcemia drugs and the adoption of treatment services, owing to its substantial population base. Regulatory reforms, favorable government policies, and enhanced healthcare infrastructure are expected to exert a positive influence on current and future market trends.
Prominent organizations, including Amgen Inc., Pfizer Inc., and Mylan N. V are at the vanguard of this sector, providing inventive solutions by capitalizing on their technological prowess and vast experience in the production of drugs. Organizations operating within this sector prioritize technological advancements, strategic alliances, and user experience improvement. These businesses make substantial investments in R&D and new medical technologies are being developed to treat the condition, the market is also influenced by advantageous reimbursement scenarios, which allow patients with low-income eligibility to pay less out-of-pocket for treatment.
Furthermore, to contend with the increasing market that is primarily motivated by concerns regarding safety and well-being, they must distinguish their products through the implementation of innovative features, robust quality standards, and comprehensive safety measures. To distinguish themselves in this highly competitive market, these businesses strive to differentiate their products. They achieve this by providing innovative treatment modalities, advanced therapeutic approaches, and personalized healthcare solutions.
New Product Launch
In May 2019, Cipla, along with its subsidiary Cipla USA, Inc., introduced generic cinacalcet hydrochloride tablets in the U.S. These tablets are utilized in the management of primary hypercalcemia in adult patients, primary hyperparathyroidism in individuals unable to undergo parathyroidectomy, secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) undergoing dialysis, and hypercalcemia in adult patients with parathyroid carcinoma.
Market Impact: By providing a generic version of cinacalcet hydrochloride, which is used in treating various forms of hypercalcemia, including primary hypercalcemia, primary hyperparathyroidism, secondary hyperparathyroidism in CKD patients on dialysis, and hypercalcemia in patients with parathyroid carcinoma, the market is likely to witness increased accessibility and affordability of this essential treatment.
In September 2021, Sunovian Pharmaceuticals revealed a collaborative partnership with Otsuka Pharmaceutical Co. The joint development and collaboration were initiated to enhance research and development efforts, with a focus on advancing the production of innovative drug compounds.
Market Impact: Through collaboration, these pharmaceutical companies seek to elevate their research and development endeavors, with a specific focus on creating novel drug compounds. This cooperative effort holds the potential to foster the development of inventive and efficacious treatments for hypercalcemia, thereby making significant contributions to market advancements.
|
Attribute |
Details |
|
Forecast Period |
2023 to 2030 |
|
Historical Data Available for |
2018 to 2022 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Product:
By Distribution Channel:
By Region:
To know more about delivery timeline for this report Contact Sales
The market is anticipated to grow at a CAGR of 11.8% during the projected period.
The global hypercalcemia treatment market was valued at US$18.3 million in 2023.
The US held the largest market share in 2023.
Some of the prominent players in the market are Amgen Inc., Pfizer Inc., Mylan N. V., Sunovion, and Procter and Gamble.
The bisphosphonates segment is expected to grow at the fastest CAGR during the forecast period.
